RecruitingPhase 1NCT07042100

A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors.

A Phase 1, Multicentre, Open-label, Multiple-dose Study to Determine Safety, Tolerability, and Preliminary Efficacy of SBO-154 in Subjects With Advanced Solid Tumors

Sponsor

Sun Pharma Advanced Research Company Limited

Enrollment

177 participants

Start Date

Aug 12, 2025

Study Type

INTERVENTIONAL

Conditions

Advanced Solid Tumors

Summary

This is a Phase 1 study of SBO-154 in patients with advanced cancers who are unable to tolerate or have not previously responded to standard therapy available in the country. The study involves multiple doses and takes place at several centers.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called DL2, a biological treatment called DL3, and others for people with advanced solid tumors. The study is currently recruiting participants at 15 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALDose level (DL)1

Administered IV every 3 weeks

BIOLOGICALDL2

Administered IV every 3 weeks

BIOLOGICALDL3

Administered IV every 3 weeks

BIOLOGICALDL4

Administered IV every 3 weeks

BIOLOGICALDL5

Administered IV every 3 weeks

Locations(16)

Honorhealth Research Institute

Scottsdale, Arizona, United States

Sarcoma Oncology Research Center

Santa Monica, California, United States

Yale University - Yale Cancer Center

New Haven, Connecticut, United States

Hope and Healing Clinical Research LLC

Hinsdale, Illinois, United States

MD Anderson Cancer Center

Houston, Texas, United States

Scientia Clinical Research

Randwick, New South Wales, Australia

Sunshine Coast University Private Hospital

Birtinya, Queensland, Australia

Cancer Research South Australia

Adelaide, South Australia, Australia

Kainos Super Speciality Hopsital

Rohtak, Haryana, India

Amrita Institute of Medical Sciences

Ernākulam, Kerala, India

Sir H.N Reliance Foundation Hospital

Mumbai, Maharashtra, India

Tata Memorial hospital

Mumbai, Maharashtra, India

Noble Hospital Pvt. Ltd.

Pune, Maharashtra, India

All India Institute for Medical Sciences

Delhi, New Delhi, India

S.P. Medical College and AG of Hospitals

Bikaner, Rajasthan, India

Pacific Medical College and Hospital

Udaipur, Rajasthan, India

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07042100

Related Trials

A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)

NCT0506728375 locations

A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors

NCT0679255217 locations

Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

NCT0691575316 locations

A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors

NCT075243486 locations

Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

NCT042224132 locations